Bioniche Life Sciences Inc. Enters into an Exclusive U.S. Distribution Agreement for an Equine Product
- MitoHorseTM is a probiotic capsule for horses -
BELLEVILLE, ON, Aug. 13, 2012 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has entered into a distribution agreement with Imagilin Technology LLC, a U.S.-based veterinary pharmaceutical company to distribute MitoHorseTM, an equine probiotic.
Probiotics work by ensuring a proper balance of good bacteria in the body to enable the absorption of food and nutrients so that the intestines are not overrun with toxins and waste. With a balanced intestinal system, the body is better able to fight illness and inflammation and help prevent the onset of disease (Lin et al, 2009).
MitoHorse™ is a special formula of two beneficial microorganisms, Pediococcus acidilactici, and Saccharomyces boulardii. Both microorganisms are naturally found in animal and human intestines. The formula is designed for the long GI tracts of horses and ponies. When horses and ponies are under stress from environmental changes, they often experience digestive disorders and have weakened immune systems. Experimental studies have demonstrated that horses and ponies fed with MitoHorse™ suffer from fewer stress-related digestive discomforts (Wilson, DA, 2012).
"This product is a welcome addition to the U.S. product portfolio, complementing our existing line of equine feed supplements and the recently introduced Gastrafate®, a GI mucosal protectant that promotes self-healing of equine gastric ulcer syndrome," said Mr. Andrew Grant, President of Bioniche Animal Health (global).
About Imagilin Technology LLC
Founded in 2003, Imagilin Technology, is a biotechnology company located in Maryland, USA. The company specializes in innovative products and technology to improve human and animal health and nutrition. Imagilin Technology focuses on probiotics as an essential part of nutraceutical products to support human and animal immune and digestive systems. The company has successfully introduced MitoMax®, a patent-pending probiotic product line for animals, to the pet industry and has established close distribution partnerships in North and South America, and Asia. MitoHorseTM is the equine formulation of this product line. The company has been closely involved with basic research and clinical studies worldwide for all of its products. The results of the research have been published in several scientific magazines and journals.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value.
Bioniche Animal Health develops, manufactures and markets veterinary biopharmaceutical products worldwide. In North America, it has development, manufacturing and marketing facilities in Belleville, Ontario, Canada, Athens, Georgia, U.S.A. and Pullman, Washington, U.S.A. In Australia, business is conducted from two sites: Sydney, New South Wales, where sales and marketing, customer support and technical service are located; and Armidale, New South Wales, where research, development and manufacturing facilities are located.
Bioniche Life Sciences Inc. has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2011. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
SOURCE: Bioniche Life Sciences Inc.For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097